Mortality, vs 0-2 1.62 ≥5 colon cancer, women Mortality, JACC, vs 0-2 1.06 ≥5 Age, alcohol consumption, colon cancer, Prospective Resident times/week Kojima, 2004 115/ BMI, educational level, family men Cohort, registry and COL01840 107 824 Questionnaire history of specific cancer, Mortality Age: 40-79 death Mortality, Japan 10 years physical activity, region of vs 0-2 0.80 years, certificates ≥5 rectal cancer, enrollment, smoking status times/week M/W men Mortality, vs 0-2 0.53 ≥5 rectal cancer, times/week women Life Span Trial, Prospective Cohort, Age, sex, alcohol Sauvaget, 2003 226/ Mortality, Age: 34-103 vs 0-1 0.97 consumption, BMI, city, ≥7 COL00521 38 540 Population FFQ colorectal Mortality years, serving/week educational level, radiation Japan 16 years cancer, M/W, dose, smoking habits subjects were atomic-bomb survivors Incidence, colorectal Q 5 vs Q 1 0.83 EPIC, cancer, 2002 Prospective 773/ Not specified FFQ COL00950 Cohort, 406 439 Incidence, vs 0-114 Europe M/W ≥372 colorectal 0.86 g/day cancer, women
Kojima, 2004 COL01840 Japan JACC, Prospective Cohort, Age: 40-79 years, M/W 115/ 107 824 10 years Resident registry and death certificates Questionnaire Mortality, colon cancer, women ≥5 vs 0-2 1.62 Age, alcohol consumption, BMI, educational level, family history of specific cancer, physical activity, region of enrollment, smoking status Mortality Mortality, colon cancer, men ≥5 vs 0-2 times/week 1.06 Mortality, rectal cancer, men ≥5 vs 0-2 times/week 0.80 Mortality, rectal cancer, women ≥5 vs 0-2 times/week 0.53 Sauvaget, 2003 COL00521 Japan Life Span Prospective Cohort, Age: 34-103 years, M/W, subjects were atomic-bomb survivors 226/ 38 540 16 years Population FFQ Mortality, colorectal cancer, ≥7 vs 0-1 serving/week 0.97 Age, sex, alcohol consumption, BMI, city, educational level, radiation dose, smoking habits Mortality 2002 COL00950 Europe EPIC, Prospective Cohort, M/W 773/ 406 439 Not specified FFQ Incidence, colorectal cancer, Q 5 vs Q 1 0.83 Incidence, colorectal cancer, women ≥372 vs 0-114 g/day 0.86 Trial,